PharmaTher Partners With TSRL For Microneedle Patch Development
PharmaTher Holdings (CSE: PHRM) has partnered with that of TSRL under a co-development agreement. The arrangement will see the two firms jointly develop a microneedle array patch focused on the incorporation of psychedelics, such as ketamine, psilocybin, DMT, MDMA, and LSD, as well as antiviral medications.
TSRL is a firm focused on developing microneedle patches that targets the delivery of antivirals for the treatment of influenza. Together, the firms will look to control the manufacturing and supply of patches for clinical and commercial drug programs being undertaken by both companies.
The patch to be used is based on tech licensed from Queens University of Belfast, with the resulting product to be focused on improving safety, efficacy, and compliance of compounds that currently are not delivered via such tech. Instead, psychedelic and antiviral compounds are commonly delivered orally, intravenously, inhaled, or injected.
“We are very excited to collaborate with TSRL as they have de-risked certain technical and manufacturing aspects of the microneedle patch and by sharing our resources it will allow PharmaTher to expedite the clinical and commercial development of the microneedle patch with ketamine and other psychedelics. Also, the collaboration will ensure control over the manufacturing and supply of microneedle patches for not only both of our respective product programs, but also it may unlock future commercial partnering opportunities with pharmaceutical companies seeking a microneedle patch delivery system.”
Fabio Chianelli, CEO of PharmaTher
TSRL thus far has successfully conducted pre-IND meetings with the US FDA, for which it has come to an agreement with the firm for their product development plans. The company is currently classified as a pre-clinical accelerator for anti-infective therapeutic product concepts.
PharmaTher last traded at $0.28 on the CSE.
FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
